Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

Please add ResearchGrants@BrightFocus.org to your institution’s white list to insure that the notification is not blocked by your organization’s SPAM filters.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

 
 
BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

Alzheimer's Disease Research
Current Award

Photo Pending

Nicholas M. Kanaan, Ph.D.

Michigan State University
East Lansing, MI

Title: Tau Oligomers and Their Potential Role in Toxicity Leading to Alzheimer's Disease
Non-Technical Title: Are Tau Oligomers the Elusive Toxic Species of Tau within Alzheimer's Disease?

Acknowledgements: This grant was transferred to Dr. Nicholas M. Kanaan upon the passing of the original PI, Dr. Lester "Skip" Binder in November 2013. The research project is being continued in Skip's memory.
Duration: August 16, 2013 - June 30, 2016
Award Type: Standard
Award Amount: $250,000

Summary:

Tau is one of the main proteins that is responsible for causing Alzheimer's disease (AD). Tau can have many different structures and we would like to identify the structure that leads to AD. If we are successful in doing so, we believe we can then target these particular structures for therapy.

Details:

Upon completion of this project, we hope to show that tau oligomers are the toxic tau species involved in Alzheimer’s disease and other tauopathies. The tau protein exists within humans as six different isoforms (versions), varying in length and composition. Dr. Binder’s team is testing the hypothesis that each of these forms of the tau aggregate, and that different aggregation conditions can lead the proteins to form into different structures (called oligomers or filaments). Recently, evidence suggests that neurofibrillary tangles (NFTs) may not be responsible for causing toxicity within the brain. Dr. Binder’s laboratory generated two novel antibodies (TOC1 and TNT1) to help them to investigate whether all oligomers are toxic. The team will assess how well each antibody binds to each species of tau aggregate. TOC1 is selective for tau oligomers only, and TNT1 binds to a sticky region of tau protein, called the PAD region, which is unmasked in the diseased brain. They will examine TOC1 and TNT1’s relative affinities for oligomers purified from the brains donated by late patients who had AD, Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD). Since we are the only one with access to both these antibodies, we feel we have the necessary tools to investigate this important question.

Secondly, Dr. Binder’s team is investigating whether all tau oligomers are toxic. Following purification of oligomers, the team will use a special test, called the cell viability assay, to monitor for cell death. This will be extended further, with toxicity testing also being carried out by collaborators at Woods Hole, MA. This will allow the team to investigate if these oligomers are having an effect on an internal nerve cell protein transport process called Fast Axonal Transport (FAT), since inhibition of FAT is a hallmark of AD.

Recently tau oligomers have gained a lot of attention, and Dr. Binder’s team possesses unique tools—the TOC1 and TNT1 antibodies—that could be used for high-throughput screens for drugs, peptides, or small molecule compounds which could prevent oligomerization of the tau protein, and prevent unmasking of the PAD domain, thereby alleviating toxicity. Prevention of these abnormal changes in tau could inhibit the signaling cascade that leads to defects in FAT in patients with tauopathies (diseases like AD, CBD, and PSP).

Dr. Binder’s team strongly believes that tau oligomers are the toxic tau species thought to be responsible for the neurodegeneration found in many tauopathies. Although oligomers formed in each of the numerous tauopathies are likely somewhat diverse in structure, the team’s TOC1 antibody has thus far recognized tau oligomers in AD, PSP, CBD, and Chronic traumatic encephalopathy (CTE, as can be found in the brains of NFL players). The proposed studies should give clues as to the conformation of the toxic aggregate and its region of toxicity.

Investigator Biography:

Dr. Binder just accepted the position of Professor of Translational Science & Molecular Medicine and Research Director in the Division of Clinical Neurosciences in the College of Human Medicine at Michigan State University.  Here he is charged with building an Alzheimer’s Disease Research Group as well as a group of Physician Scientists who work on neurodegenerative diseases. Previous to this, Dr. Binder was Professor of Cell and Molecular Biology and held the Abbott Labs/Burnham Chair in Genetic and Molecular Medicine at the Feinberg School of Medicine, Northwestern University. Previous to this, he held positions in a biotechnology company and was on faculty at the University of Alabama at Birmingham School of Medicine. His laboratory has always worked on the neuronal protein, tau, which forms the neurofibrillary tangles in the brains of patients with AD but also is involved in frontotemporal dementias as well as traumatic brain injuries suffered by NFL football players and soldiers.